Literature DB >> 34713633

Modulating hypoxia inducible factor-1 by nanomaterials for effective cancer therapy.

Yun Sun1, Zhiguo Zhou1, Shiping Yang1, Hong Yang1.   

Abstract

Hypoxia, which is induced by abnormal tumor growth when it outstrips its oxygen supply, is a major character of cancer. The reaction of cells against hypoxia is mainly concentrated on the hypoxia-induced transcription factors (HIFs), especially HIF-1, which remain stabilized during hypoxia. Additionally, the oxygen-independent mechanism of regulating HIF-1 acts a vital part in different stages of tumor progression as well as chemo-/radio-/PDT resistance, resulting in poor curative effects and prognosis. In this review, we will outline the up-to-date information about how HIF-1 interferes with tumor metastasis and therapy resistance, followed by a detailed introduction of motivating techniques based on various nanomaterials to interfere with HIF signaling for effective cancer therapy. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Emerging Technologies Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  HIF-1; cancer therapy; nanomaterials

Mesh:

Substances:

Year:  2021        PMID: 34713633     DOI: 10.1002/wnan.1766

Source DB:  PubMed          Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol        ISSN: 1939-0041


  2 in total

Review 1.  Progress of Nanomaterials in Photodynamic Therapy Against Tumor.

Authors:  Lei Chen; Jiahui Huang; Xiaotong Li; Miaoting Huang; Shaoting Zeng; Jiayi Zheng; Shuyi Peng; Shiying Li
Journal:  Front Bioeng Biotechnol       Date:  2022-05-31

2.  Hypoxia induces docetaxel resistance in triple-negative breast cancer via the HIF-1α/miR-494/Survivin signaling pathway.

Authors:  Hongchang Li; Xianhao Sun; Jindong Li; Weiyan Liu; Gaofeng Pan; Anwei Mao; Jiazhe Liu; Qing Zhang; Longhua Rao; Xiaofeng Xie; Xia Sheng
Journal:  Neoplasia       Date:  2022-08-17       Impact factor: 6.218

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.